{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462248957
| IUPAC_name = 5-Amino-2-hydroxybenzoic acid
| image = Mesalazine structure.svg
| width = 171
<!--Clinical data-->
| tradename = Many names worldwide, including Azacol, Lialda, Pentasa, and Apriso<ref name=generics>Drugs.com [https://www.drugs.com/ingredient/mesalamine.html International trade names for mesalazine] April 20, 2016</ref>
| Drugs.com = {{drugs.com|monograph|mesalamine}}
| pregnancy_US = B
| pregnancy_category =
| legal_US = Rx-only
| legal_status =
| routes_of_administration = oral, [[rectal]]
| licence_US = Mesalazine
| MedlinePlus = a688021
| DailyMedID = 47586
<!--Pharmacokinetic data-->
| bioavailability = orally: 20–30% absorbed<br>rectally: 10–35%
| metabolism = Rapidly & extensively metabolised intestinal mucosal wall and the liver
| elimination_half-life = 5 hours after initial dose.<br>At steady state 7 hours
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89-57-6
| ATC_prefix = A07
| ATC_suffix = EC02
| PubChem = 4075
| IUPHAR_ligand = 2700
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00244
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3933
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4Q81I59GXC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00377
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6775
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 704
<!--Chemical data-->
| C=7 | H=7 | N=1 | O=3
| molecular_weight = 153.135 g/mol
| smiles = O=C(O)c1cc(ccc1O)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KBOPZPXVLCULAV-UHFFFAOYSA-N
}}

'''Mesalazine''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]), also known as '''mesalamine''' ([[United States Adopted Name|USAN]]) or '''5-aminosalicylic acid''' ('''5-ASA'''), is an [[aminosalicylate]]  [[anti-inflammatory]] drug<ref name="PharmGKB" >[http://www.pharmgkb.org/drug/PA450384#tabview=tab2&subtab=31 "mesalazine"]. PharmGKB.</ref>  used to treat [[inflammatory bowel disease]], including [[ulcerative colitis]],<ref name=UKOralLabel/><ref name=UKSuppLabel/><ref name=UKEnemaLabel/> or [[proctitis|inflamed anus or rectum]],<ref name=USSuppLabel/> and to maintain [[remission (medicine)|remission]] in [[Crohn's disease]].<ref name=UKOralLabel/><ref>{{cite journal|vauthors=Sandborn WJ, Feagan BG, Lichtenstein GR | title = Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission| journal = Alimentary Pharmacology & Therapeutics| volume = 26| issue = 7| pages = 987–1003| date=October 2007| pmid = 17877506| doi = 10.1111/j.1365-2036.2007.03455.x| url = http://www3.interscience.wiley.com/cgi-bin/fulltext/117987903/HTMLSTART| accessdate = 2009-12-20}}</ref>

It is sold in an oral form to maintain remission in Crohn's disease,<ref name=UKOralLabel>UK Electronic Medicines Compendium [https://www.medicines.org.uk/emc/medicine/12583 UL Oral Label] Last revised December 2015</ref> and as a [[rectal suppository]]<ref name=UKSuppLabel>UK Electronic Medicines Compendium [https://www.medicines.org.uk/emc/medicine/11571 Suppository Label] Last revised February 2016</ref><ref name=USSuppLabel>FDA. [http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204354Orig1s000lbl.pdf US Suppository Label] Last updated Nov 2015</ref> and an [[enema]] for the lower bowel conditions.<ref name=UKEnemaLabel>UK Electronic Medicines Compendium [https://www.medicines.org.uk/emc/PIL.11577.latest.pdf UK Enema Label] Last revised  January 2016</ref>  It is generic and sold under many brand names worldwide,<ref name=generics/> and there are many formulations.<ref>Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):137-44. {{PMID|26558148}} [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635154/ PMC 4635154]</ref>

There are no data on use in pregnant women, but the drug does cross the placenta and is excreted in [[breast milk]].  The drug should not be used in children under two, people with [[kidney disease]], or people who are allergic to [[aspirin]].<ref name=UKSuppLabel/>

Side effects are primarily gastrointestinal but may also include headache; GI effects include nausea, diarrhea and abdominal pain.  There have been scattered reports of various problems when the oral form is used, including:problems caused by [[myelosuppression]] ([[leukopenia]], [[neutropenia]], [[agranulocytosis]], [[aplastic anaemia]], and [[thrombocytopenia]]), as well as hair loss, [[peripheral neuropathy]], [[pancreatitis]], liver problems, [[myocarditis]] and [[pericarditis]], allergic and fibrotic lung reactions, [[lupus erythematosus]]-like reactions and rash (including [[urticaria]]), [[drug fever]], [[interstitial nephritis]] and [[nephrotic syndrome]], usually reversible on withdrawal.  Very rarely, use of mesalazine has been associated with an exacerbation of the symptoms of [[colitis]], [[Stevens Johnson syndrome]] and [[erythema multiforme]].<ref name=UKOralLabel/><ref name=UKSuppLabel/>

Mesalazine is the active [[Functional group|moiety]] of [[sulfasalazine]], which is metabolized to [[sulfapyridine]] and mesalazine.<ref>''Lippencott's Illustrated Reviews: Pharmacology'', 4th Ed. Finkel, Cubeddu and Clark</ref> It is also the active component of the prodrug [[balsalazide]] along with the inert carrier molecule 4-aminobenzoyl-beta-alanine.<ref>Drugs & Therapy Properties 2003 Oct; Vol 19, No. 10</ref>

==References==
{{reflist|30em}}
<!--not actually used as refs* {{cite book | editor-last = Mehta | editor-first = Dinesh K | title=[[British National Formulary]] | volume=45 |date=March 2003 | publisher=Pharmaceutical Press | location=London | isbn= 0-85369-555-5 }}
* {{cite book | editor-last = Sweetman | editor-first = Sean C | title=[[Martindale: The complete drug reference]] | edition=34th |date=November 2004 | publisher=Pharmaceutical Press | location=London | isbn= 0-85369-550-4 }}-->

<!-- ==External links== -->
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
{{Prostanoidergics}}

[[Category:Anilines]]
[[Category:Anti-inflammatory agents]]
[[Category:Gastroenterology]]
[[Category:Salicylic acids]]
[[Category:Antioxidants]]